ESMO Breast 2022 | Exploring myeloid cells to reverse the hormone-mediated microenvironemnt of luminal breast cancer

Céline Blaye, MD, University of Bordeaux, Bordeaux, France, discusses the transforming landscape of immunotherapy for the treatment of breast cancer, including the hormone-mediated microenvironment of luminal breast cancer. This type of environment impairs immunotherapeutic strategies, providing the rationale for investigating myeloid cells to evaluate whether this can be reversed to render immunotherapeutic strategies efficacious in this disease setting. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.